Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 376

1.

Rational bases for the development of EGFR inhibitors for cancer treatment.

Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.

Int J Biochem Cell Biol. 2007;39(7-8):1416-31. Epub 2007 May 21. Review.

PMID:
17596994
2.

Epidermal growth factor receptor (EGFR) signaling in cancer.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS.

Gene. 2006 Jan 17;366(1):2-16. Epub 2005 Dec 27. Review.

PMID:
16377102
3.

ErbB-targeted therapeutic approaches in human cancer.

Arteaga CL.

Exp Cell Res. 2003 Mar 10;284(1):122-30. Review.

PMID:
12648471
4.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
5.

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

Bianco R, Troiani T, Tortora G, Ciardiello F.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S159-71. Review.

PMID:
16113092
6.

Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.

Lage A, Crombet T, González G.

Ann Med. 2003;35(5):327-36. Review.

PMID:
12952019
7.

EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.

Kataoka H.

J Dermatol Sci. 2009 Dec;56(3):148-53. doi: 10.1016/j.jdermsci.2009.10.002. Epub 2009 Nov 6. Review.

PMID:
19896805
8.

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

Tiseo M, Loprevite M, Ardizzoni A.

Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. Review.

PMID:
15032719
9.

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

Mendelsohn J, Baselga J.

J Clin Oncol. 2003 Jul 15;21(14):2787-99. Review.

PMID:
12860957
10.

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA.

Expert Opin Ther Targets. 2005 Oct;9(5):1009-30. Review.

PMID:
16185155
11.

Targeting epidermal growth factor receptor in head and neck cancer.

Ford AC, Grandis JR.

Head Neck. 2003 Jan;25(1):67-73. Review.

PMID:
12478546
12.

Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.

Ghosh S, Liu XP, Zheng Y, Uckun FM.

Curr Cancer Drug Targets. 2001 Aug;1(2):129-40. Review.

PMID:
12188886
13.

Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

Mamot C, Rochlitz C.

Swiss Med Wkly. 2006 Jan 7;136(1-2):4-12. Review.

PMID:
16597093
14.

Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.

Forsberg S, Ostman A, Rollman O.

Arch Dermatol Res. 2008 Oct;300(9):505-16. doi: 10.1007/s00403-008-0853-2. Epub 2008 Apr 30.

PMID:
18446355
15.

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.

Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, Gerald WL, Pincus MR, Osman I, Lee P.

Oncogene. 2008 May 15;27(22):3201-10. doi: 10.1038/sj.onc.1210983. Epub 2008 Jan 14.

PMID:
18193092
16.

Efficacy of ligand-based targeting for the EGF system in cancer.

Yotsumoto F, Sanui A, Fukami T, Shirota K, Horiuchi S, Tsujioka H, Yoshizato T, Kuroki M, Miyamoto S.

Anticancer Res. 2009 Nov;29(11):4879-85. Review.

17.

[Role of predictive pathology in oncology--example of new therapies targeting EGFR].

Hartmann A.

Verh Dtsch Ges Pathol. 2006;90:128-35. German.

PMID:
17867589
18.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

Dassonville O, Bozec A, Fischel JL, Milano G.

Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. Epub 2007 Feb 26. Review.

PMID:
17324578
19.

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

Reid A, Vidal L, Shaw H, de Bono J.

Eur J Cancer. 2007 Feb;43(3):481-9. Epub 2007 Jan 8. Review.

PMID:
17208435
20.

Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands.

Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N.

Cancer Sci. 2008 Feb;99(2):214-20. doi: 10.1111/j.1349-7006.2007.00676.x. Review.

Supplemental Content

Support Center